Report Detail

Pharma & Healthcare Eloxx Pharmaceuticals Inc (ELOX) - Financial and Strategic SWOT Analysis Review

  • RnM3185408
  • |
  • 25 March, 2019
  • |
  • Global
  • |
  • 45 Pages
  • |
  • GlobalData
  • |
  • Pharma & Healthcare

Eloxx Pharmaceuticals Inc (ELOX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eloxx Pharmaceuticals Inc(Eloxx) formerly known as Sevion Therapeutics Inc, is a biopharmaceutical company that discovers, develops and acquires innovative product candidates for the treatment of cancer and immunological diseases. The company has developed protein nanocage system that allows delivery of nucleic acids and other payloads to target cells. Its product pipeline comprises SVN-001, SVN-002, SVN-003, multiple GPCR targets and ion channel. The company’s SVN-002 is an antibody against an oncology target that has the potential to impact metastatic tumors, which include resistant to anti-VEGF treatments. Eloxx is headquartered in San Diego, California, the US.

Eloxx Pharmaceuticals Inc Key Recent Developments

Mar 08,2019 Eloxx Pharmaceuticals reports fourth quarter and full year 2018 financial and operating results and provides business update
Nov 08,2018 Eloxx Pharmaceuticals reports third quarter 2018 financial and operating results and provides business update
Sep 24,2018 Eloxx Pharmaceuticals To Present at the 8th Orphan Drugs & Rare Diseases Congress, the Oppenheimer Fall Summit, and the 2018 Cantor Global Healthcare Conference
Aug 07,2018 Eloxx Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Table of Contents

    Table of Contents

      List of Tables

        List of Figures

          Section 1 - About the Company

            Eloxx Pharmaceuticals Inc - Key Facts

              Eloxx Pharmaceuticals Inc - Key Employees

                Eloxx Pharmaceuticals Inc - Major Products and Services

                  Eloxx Pharmaceuticals Inc - History

                    Eloxx Pharmaceuticals Inc - Locations And Subsidiaries

                      Head Office

                        Other Locations & Subsidiaries

                          Section 2 – Company Analysis

                            Company Overview

                              Eloxx Pharmaceuticals Inc - Business Description

                                R&D Overview

                                  Eloxx Pharmaceuticals Inc - SWOT Analysis

                                    SWOT Analysis - Overview

                                      Eloxx Pharmaceuticals Inc - Strengths

                                        Eloxx Pharmaceuticals Inc - Weaknesses

                                          Eloxx Pharmaceuticals Inc - Opportunities

                                            Eloxx Pharmaceuticals Inc - Threats

                                              Eloxx Pharmaceuticals Inc - Key Competitors

                                                Section 3 – Company Financial Ratios

                                                  Financial Ratios - Capital Market Ratios

                                                    Financial Ratios - Annual Ratios

                                                      Performance Chart

                                                        Financial Performance

                                                          Financial Ratios - Interim Ratios

                                                            Financial Ratios - Ratio Charts

                                                              Section 4 – Company’s Lifesciences Financial Deals and Alliances

                                                                Eloxx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

                                                                  Eloxx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

                                                                    Eloxx Pharmaceuticals Inc, Recent Deals Summary

                                                                      Section 5 – Company’s Recent Developments

                                                                        Mar 08, 2019: Eloxx Pharmaceuticals reports fourth quarter and full year 2018 financial and operating results and provides business update

                                                                          Nov 08, 2018: Eloxx Pharmaceuticals reports third quarter 2018 financial and operating results and provides business update

                                                                            Sep 24, 2018: Eloxx Pharmaceuticals To Present at the 8th Orphan Drugs & Rare Diseases Congress, the Oppenheimer Fall Summit, and the 2018 Cantor Global Healthcare Conference

                                                                              Aug 07, 2018: Eloxx Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update

                                                                                Jun 25, 2018: Eloxx Pharmaceuticals Announces Senior Management Changes

                                                                                  Jun 18, 2018: Eloxx Names Neil Belloff As Executive Vice President, General Counsel And Corporate Secretary

                                                                                    May 10, 2018: Eloxx Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results and Provides Business Update

                                                                                      Mar 19, 2018: Eloxx Pharmaceuticals Reports Full Year 2017 Financial and Operating Results and Provides Business Update

                                                                                        Feb 28, 2018: Eloxx Pharmaceuticals Appoints Biotech Leader, Dr. Jasbir Seehra, Co-founder of Acceleron Pharma, to Board of Directors

                                                                                          Section 6 – Appendix

                                                                                            Methodology

                                                                                              Ratio Definitions

                                                                                                About GlobalData

                                                                                                  Contact Us

                                                                                                    Disclaimer

                                                                                                    Summary:
                                                                                                    Get latest Market Research Reports on Eloxx Pharmaceuticals Inc (ELOX) . Industry analysis & Market Report on Eloxx Pharmaceuticals Inc (ELOX) is a syndicated market report, published as Eloxx Pharmaceuticals Inc (ELOX) - Financial and Strategic SWOT Analysis Review. It is complete Research Study and Industry Analysis of Eloxx Pharmaceuticals Inc (ELOX) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                    Last updated on

                                                                                                    REPORT YOU MIGHT BE INTERESTED

                                                                                                    Purchase this Report

                                                                                                    $500.00
                                                                                                    $1,000.00
                                                                                                    $1,500.00
                                                                                                    386.50
                                                                                                    773.00
                                                                                                    1,159.50
                                                                                                    465.50
                                                                                                    931.00
                                                                                                    1,396.50
                                                                                                    76,345.00
                                                                                                    152,690.00
                                                                                                    229,035.00
                                                                                                    42,200.00
                                                                                                    84,400.00
                                                                                                    126,600.00
                                                                                                    Credit card Logo

                                                                                                    Related Reports


                                                                                                    Reason to Buy

                                                                                                    Request for Sample of this report